BlackRock Virginia Municipal Bond Trust BHV
12.55 USD +0.63 (+5.29%)
Nov 3, 2026, 3:59 PM EST
11.90 Day range 12.74
10.04 52-week range 15.15
- YTD
- +20.10%
- 1 year
- +11.56%
- Market cap
- 19.93M
- Revenue (ttm)
- 1.42M
- Profit margin
- 48.79%
- EPS (ttm)
- 0.77
- Shares out
- 1.59M
- P/E ratio
- 16.30
- Dividend
- 0.62 (5.57%)
- Ex-dividend date
- Dec 15, 2024
- YTD return
- +20.10%
- 1-year return
- +11.56%
- Volume
- 4.75K
- Avg volume
- 4.52K
- Open
- 11.90
- Previous close
- 11.92
- Day's range
- 11.90 – 12.74
- 52-week range
- 10.04 – 15.15
- Beta
- 0.80
2Y +1.67 (+15.09%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 12.56
- Price / book
- 0.90
- Dividend yield
- 5.57%
- Payout ratio
- 94.57%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 11.56M
- Return on equity
- 0.00%
- Short % of float
- 0.07%
- 50-day average
- 11.22
- 200-day average
- 11.11
Analyst view
Price target (mean) —
Ratings (0m) 1 0 buy · 1 hold · 0 sell
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
About BlackRock Virginia Municipal Bond Trust
Blackrock Virginia Municipal Bond Trust is a closed-ended fixed income mutual fund launched by BlackRock, Inc. It is managed by BlackRock Advisors, LLC. The fund invests in fixed income markets of United States. It primarily invests in the investment grade municipal bonds exempt from federal income taxes and Virginia personal income taxes. Blackrock Virginia Municipal Bond Trust was formed on April 25, 2002 and is domiciled in United States.
- Sector
- Financial Services
- Industry
- Asset Management
- Country
- United States
News
Weekly Closed-End Fund Roundup (October 18, 2026) 
Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy 
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease 
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026 
BlackRock Virginia Municipal Bond Trust (NYSEAMERICAN:BHV) Shares Pass Below 50 Day Moving Average – Here’s What Happened 
Biohaven: Buy Reiterated On Opakalim License Agreement For Epilepsy And More 
Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results 
Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload 
Biohaven: Nice Pipeline Momentum, But Its Runway Is A Risk 
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
Your note
Sign in to keep a note on BHV — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Saba Capital Management, L.P. | 4.39% | 70,728 | 791.45K | Sep 29, 2024 |
| Matisse Capital | 2.55% | 41,000 | 458.79K | Sep 29, 2024 |
| Morgan Stanley | 0.80% | 12,888 | 144.22K | Sep 29, 2024 |
| Logan Stone Capital, LLC | 0.74% | 11,945 | 133.66K | Sep 29, 2024 |
| Geneos Wealth Management, Inc. | 0.48% | 7,696 | 86.12K | Sep 29, 2024 |
| UBS Group AG | 0.37% | 6,011 | 67.26K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Starboard Investment Tr-Matisse Discounted Bond CEF Strategy | 2.55% | 41,000 | 458.79K | Sep 29, 2024 |
| Saba Capital Income & Opportunities Fd | 0.01% | 97 | 1.08K | Jul 30, 2024 |
| Exchange Listed Fds Tr-Saba Closed-End Funds ETF | 0.01% | 173 | 1.94K | Aug 30, 2024 |
| Rydex Series Funds-Multi-Hedge Strategies Fund | 0.01% | 220 | 2.46K | Sep 29, 2024 |
| Rydex Variable Trust-Multi Hedge Strategies Fund | 0.01% | 139 | 1.55K | Sep 29, 2024 |